
Marianne Jansson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/735238/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Tuberculosis infection and stillbirth in Ethiopia—A prospective cohort study. PLoS ONE, 2022, 17, e0261972.	2.5	3
2	HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs. International Journal of Molecular Sciences, 2022, 23, 4766.	4.1	0
3	Kynurenine/tryptophan ratio for detection of active tuberculosis in adults with HIV prior to antiretroviral therapy. Aids, 2022, 36, 1245-1253.	2.2	3
4	Tuberculosis Infection in Women of Reproductive Age: A Cross-sectional Study at Antenatal Care Clinics in an Ethiopian City. Clinical Infectious Diseases, 2021, 73, 203-210.	5.8	16
5	Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children. Vaccines, 2021, 9, 260.	4.4	2
6	Longitudinal Mycobacterium tuberculosis-Specific Interferon Gamma Responses in Ethiopian HIV-Negative Women during Pregnancy and Postpartum. Journal of Clinical Microbiology, 2021, 59, e0086821.	3.9	6
7	Inverted CD8 T-Cell Exhaustion and Co-Stimulation Marker Balance Differentiate Aviremic HIV-2-Infected From Seronegative Individuals. Frontiers in Immunology, 2021, 12, 744530.	4.8	5
8	Expression of MicroRNAs Is Dysregulated by HIV While Mycobacterium tuberculosis Drives Alterations of Small Nucleolar RNAs in HIV Positive Adults With Active Tuberculosis. Frontiers in Microbiology, 2021, 12, 808250.	3.5	1
9	Alternative biomarkers for classification of latent tuberculosis infection status in pregnant women with borderline Quantiferon plus results. Tuberculosis, 2020, 124, 101984.	1.9	7
10	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. AIDS Research and Therapy, 2020, 17, 33.	1.7	8
11	HIV-2 as a model to identify a functional HIV cure. AIDS Research and Therapy, 2019, 16, 24.	1.7	24
12	New insights are game-changers in HIV-2 disease management – Authors' reply. Lancet HIV,the, 2019, 6, e214-e215.	4.7	4
13	Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein–Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2–Infected Individuals. Journal of Infectious Diseases, 2019, 219, 1749-1754.	4.0	7
14	Plasma Profiles of Inflammatory Markers Associated With Active Tuberculosis in Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Positive Individuals. Open Forum Infectious Diseases, 2019, 6, ofz015.	0.9	13
15	Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. Lancet HIV,the, 2019, 6, e25-e31.	4.7	57
16	Low Postseroconversion CD4 + T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection. MBio, 2019, 10, .	4.1	7
17	Quantification of HIV-2 DNA in Whole Blood. Bio-protocol, 2019, 9, e3404.	0.4	1
18	Prevalence of HIV-1 pretreatment drug resistance among treatment naÃ⁻ve pregnant women in Bissau, Guinea Bissau, PLoS ONE, 2018, 13, e0206406.	2.5	11

#	Article	IF	CITATIONS
19	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	4.7	30
20	Performance of QuantiFERON-TB Gold Plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS ONE, 2018, 13, e0193589.	2.5	29
21	HIV-2 Infection: The Role of Immune Activation in Pathogenesis. , 2018, , 956-962.		Ο
22	Dendritic Cell Response to HIV-1 Is Controlled by Differentiation Programs in the Cells and Strain-Specific Properties of the Virus. Frontiers in Immunology, 2017, 8, 244.	4.8	2
23	Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections. Aids, 2016, 30, 1713-1722.	2.2	27
24	Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e79-e82.	2.1	2
25	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. Journal of Virology, 2016, 90, 9855-9861.	3.4	12
26	CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection. Aids, 2016, 30, 2415-2426.	2.2	30
27	Plasma Levels of Neopterin and C-Reactive Protein (CRP) in Tuberculosis (TB) with and without HIV Coinfection in Relation to CD4 Cell Count. PLoS ONE, 2015, 10, e0144292.	2.5	24
28	The Evolution of HIV-1 Interactions with Coreceptors and Mannose C-Type Lectin Receptors. Progress in Molecular Biology and Translational Science, 2015, 129, 109-140.	1.7	6
29	Cocirculation of Several Similar But Unique HIV-1 Recombinant Forms in Guinea-Bissau Revealed by Near Full-Length Genomic Sequencing. AIDS Research and Human Retroviruses, 2015, 31, 938-945.	1.1	3
30	Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4+ T Cells. PLoS ONE, 2014, 9, e88195.	2.5	11
31	T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. PLoS Pathogens, 2014, 10, e1004251.	4.7	273
32	Effect of HIV-2 infection on HIV-1 disease progression and mortality. Aids, 2014, 28, 614-615.	2.2	13
33	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-957.	2.2	32
34	Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. BMC Infectious Diseases, 2014, 14, 472.	2.9	4
35	Faster Progression to AIDS and AIDS-Related Death Among Seroincident Individuals Infected With Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. Journal of Infectious Diseases, 2014, 209, 721-728.	4.0	33
36	Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein. Journal of Immunology, 2014, 192, 5802-5812.	0.8	4

MARIANNE JANSSON

#	Article	IF	CITATIONS
37	Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals. Aids, 2014, 28, 949-57.	2.2	9
38	Effect of Complement on HIV-2 Plasma Antiviral Activity Is Intratype Specific and Potent. Journal of Virology, 2013, 87, 273-281.	3.4	11
39	R5 human immunodeficiency virus type 1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children. Journal of General Virology, 2013, 94, 767-773.	2.9	2
40	Frequent Intratype Neutralization by Plasma Immunoglobulin A Identified in HIV Type 2 Infection. AIDS Research and Human Retroviruses, 2013, 29, 470-478.	1.1	10
41	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Human Vaccines and Immunotherapeutics, 2013, 9, 2103-2110.	3.3	3
42	Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model. PLoS ONE, 2013, 8, e74552.	2.5	12
43	Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines, 2013, 1, 305-327.	4.4	10
44	HIV-2 Infection: The Role of Immune Activation in Pathogenesis. , 2013, , 1-8.		0
45	Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1. Journal of Virology, 2012, 86, 961-971.	3.4	39
46	Tuberculosis and HIV Co-Infection. PLoS Pathogens, 2012, 8, e1002464.	4.7	549
47	Inhibition of HIV-1 Disease Progression by Contemporaneous HIV-2 Infection. New England Journal of Medicine, 2012, 367, 224-232.	27.0	94
48	Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. Aids, 2012, 26, 1739-1744.	2.2	3
49	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	2.5	63
50	Mycobacteriaâ€infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate <scp>HIV</scp> transinfection. European Journal of Immunology, 2012, 42, 1192-1202.	2.9	8
51	Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge. PLoS ONE, 2011, 6, e20135.	2.5	16
52	Reply to Redd et al. Journal of Infectious Diseases, 2011, 203, 746-746.	4.0	0
53	Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques. Journal of Virology, 2011, 85, 6442-6452.	3.4	16
54	Microbial Translocation Correlates with the Severity of Both HIVâ€1 and HIVâ€2 Infections. Journal of Infectious Diseases, 2010, 201, 1150-1154.	4.0	99

MARIANNE JANSSON

#	Article	IF	CITATIONS
55	Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid Isolates. AIDS Research and Human Retroviruses, 2009, 25, 1297-1305.	1.1	13
56	Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine, 2009, 46, 325-331.	3.2	23
57	Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine, 2009, 28, 270-278.	3.8	13
58	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology, 2008, 379, 125-134.	2.4	45
59	Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology, 2008, 5, 28.	2.0	21
60	Suppression of HIV Replication In Vitro by CpG and CpG Conjugated to the Non Toxic B Subunit of Cholera Toxin. Current HIV Research, 2008, 6, 230-238.	0.5	5
61	Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology, 2005, 86, 2859-2869.	2.9	56
62	Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. Journal of General Virology, 2005, 86, 3385-3396.	2.9	69
63	T-bet-dependent expression of osteopontin contributes to T cell polarization. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17101-17106.	7.1	138
64	Coreceptor Usage of Primary HIV Type 1 Isolates Obtained from Different Lymph Node Subsets. AIDS Research and Human Retroviruses, 2005, 21, 1003-1010.	1.1	0
65	Coevolution of RANTES Sensitivity and Mode of CCR5 Receptor Use by Human Immunodeficiency Virus Type 1 of the R5 Phenotype. Journal of Virology, 2004, 78, 11807-11815.	3.4	81
66	Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis. Arthritis and Rheumatism, 2004, 50, 2685-2694.	6.7	25
67	Cutting Edge: Attenuated Experimental Autoimmune Encephalomyelitis in Eta-1/Osteopontin-Deficient Mice. Journal of Immunology, 2002, 168, 2096-2099.	0.8	169
68	CCR5 or CXCR4 Is Required for Efficient Infection of Peripheral Blood Mononuclear Cells by Promiscuous Human Immunodeficiency Virus Type 2 Primary Isolates. AIDS Research and Human Retroviruses, 2002, 18, 193-200.	1.1	20
69	Length Variation of Glycoprotein 120 V2 Region in Relation to Biological Phenotypes and Coreceptor Usage of Primary HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 2001, 17, 1405-1414.	1.1	33
70	Eta-1 (Osteopontin): An Early Component of Type-1 (Cell-Mediated) Immunity. Science, 2000, 287, 860-864.	12.6	1,042
71	Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants. Aids, 1997, 11, 1709-1717.	2.2	31
72	The Role of Virologic and Immunologic Factors in Motherâ€ŧoâ€Child Transmission of HIVâ€1. American Journal of Reproductive Immunology, 1997, 38, 197-200.	1.2	8

#	Article	IF	CITATIONS
73	Interferon Alpha-Inducible Protein 27 Expression Is Linked to Disease Severity in Chronic Infection of Both HIV-1 and HIV-2. Frontiers in Virology, 0, 2, .	1.4	3